Bio-Techne Reports Fourth Quarter and Full Year 2026 Financial Results and Declares Dividend

Details

The company's fourth quarter organic revenue increased by 3% to $321.2 million, while full year organic revenue remained flat at $1.2 billion. GAAP EPS for the fourth quarter was $0.35, up from $(0.11) in the same quarter last year. Full year GAAP EPS increased to $1.16 from $0.46 in the prior year. Additionally, Bio-Techne declared a cash dividend of $0.25 per share, payable on September 30, 2026, to shareholders of record as of September 16, 2026.

Items reported

About Bio-Techne Corporation

Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.